By Dominic Tyer (European Pharmaceutical Review)2025-08-20T11:27:31
The drug is the first treatment for desmoid tumours to be approved in the region.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-05-29T10:14:00Z
2026-05-22T14:48:00Z
Sponsored by CPhI
2026-05-21T08:24:00Z
2026-04-30T10:37:00
Sponsored by Shimadzu
2026-03-27T15:37:00
Sponsored by IMA Pharma
2026-05-27T13:00:00 2026-05-27T14:00:00
Sponsored by TA Instruments
2025-09-17T08:00:00
Sponsored by Mastercontrol
2025-10-22T14:00:00
Sponsored by Bruker
2026-05-22T14:48:00
Sponsored by CPhI
Site powered by Webvision Cloud